Approximately 3,000 people are diagnosed with mesothelioma in the United States each year, with roughly 30,000 new cases diagnosed worldwide. The median age at diagnosis is 72 years, approximately 80% of patients are male, and veterans represent an estimated 30% of all diagnoses. The 5-year survival rate across all stages is approximately 12%, though outcomes vary significantly by type, stage, and treatment approach.
Key Statistics at a Glance
| Metric | Value | Source |
|---|---|---|
| Annual U.S. diagnoses | ~3,000 | NCI/SEER |
| Global annual diagnoses | ~30,000 | WHO/IARC |
| Median age at diagnosis | 72 years | SEER |
| Gender distribution | ~80% male, ~20% female | SEER |
| Veterans percentage | ~30% of diagnoses | VA/DOD estimates |
| Latency period | 20–50 years | NCI |
| 5-year survival (all stages) | ~12% | ACS |
| 5-year survival (localized) | ~20% | SEER |
| 5-year survival (peritoneal + HIPEC) | 50–60% | Published HIPEC studies |
| Active trust funds | 60+ | Public trust records |
| Trust fund assets remaining | $30+ billion | Trust fund filings |
Demographic Patterns
The 80/20 male-to-female ratio reflects historical occupational exposure patterns — men disproportionately worked in industries with heavy asbestos use (construction, shipbuilding, manufacturing). However, women also develop mesothelioma through secondary exposure (washing contaminated work clothes) and environmental exposure. Hispanic workers are disproportionately represented in high-risk occupations including construction, refinery maintenance, and demolition.
Trends
While overall U.S. mesothelioma incidence has plateaued, cases continue because asbestos was not banned until 2024, legacy asbestos remains in millions of buildings, and the 20–50 year latency period means workers exposed in the 1980s and 1990s are now being diagnosed. Globally, mesothelioma rates continue to rise in developing nations where asbestos use has not been curtailed.